Skip to main content
Premium Trial:

Request an Annual Quote

BioForce Nanosciences Inks Licensing, Equity Agreement with Spinout Aspera

NEW YORK (GenomeWeb News) - BioForce Nanosciences Holdings said today that it has signed a licensing and equity agreement with Aspera, a startup founded by former employees of BioForce with the goal of developing miniaturized biomolecular detection systems for point-of-care diagnostics. 
 
Under the terms of the agreement, BioForce licensed several of its technologies to Aspera on a non-exclusive basis, including its ViriChip, Chip-on-a-Tip, and CellWell diagnostic and detection systems, in exchange for royalties on any revenue generated by Aspera from the licensed technology.
 
Aspera’s founders were involved in the development of the licensed technologies. BioForce said that four of its employees who were involved in the development of the systems, as well as governmental grants supporting the development of the technology, will be transferred to Aspera.
 
In addition, BioForce said it will take a 19 percent equity interest in Aspera.
 
Greg Brown, CFO of BioForce, said in a statement that the transaction, “along with other organizational adjustments which have been recently made, reduces our net cash expenses by approximately $500,000 per year,” or approximately 20 percent.
 
“Realizing meaningful cost savings via this transaction with Aspera, as an alternative to curtailing some or all research and development activities on the scientific applications in order to achieve the cost savings, was a much better alternative for our shareholders,” he added.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.